Weight-Loss Medications Market Projected to Reach $60 Billion in 10 Years
According to a Morningstar analyst, frantic demand for pharmaceuticals to treat obesity from Novo Nordisk, Eli Lilly, and other companies might sustain a global market worth eye-popping $60 billion in the following ten years. By 2032, the market share of Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide) and a follow-up combination called CagriSema, which is based … Read more
